Sparks Fly: Pfizer and Icagen Unite To Study Sodium Ion Channels For Pain
This article was originally published in The Pink Sheet Daily
Executive Summary
Targets in the deal are important in generation of electrical signals in nerve fibers that mediate the initiation and sensation of pain, firms say.
You may also be interested in...
Pfizer Looks To Buy Icagen To Fold Into Neusentis Pain Research Unit
Pfizer plans to buy its pain partner in a deal valued at $56 million, including the 11% of shares the big pharma already owns in Icagen.
Pfizer Looks To Buy Icagen To Fold Into Neusentis Pain Research Unit
Pfizer plans to buy its pain partner in a deal valued at $56 million, including the 11% of shares the big pharma already owns in Icagen.
Icagen CEO P. Kay Wagoner: An Interview With "The Pink Sheet" DAILY
Firm's leader discusses pipeline and partnership with Pfizer.